

Day 1, 27 <sup>th</sup> September 2016					
07.30	<b>Registration &amp; Coffee</b>				
08.10	Welcome Speech by Beth Jacobs, Managing Partner, Excellentia Global Partners				
08.20	<b>State of the Markets: Pharma and Biotech</b> Chaired by: Stephanie Léouzon, Partner, Torrey Partners (Europe), LLC - Panellists: 09.05 Chandra Leo, Investment Advisor, HBM Partners AG Isabella Schidrich, Senior Managing Director, NASDAQ Ryan Richardson, Vice President, Healthcare Investment Banking, JP Morgan Healthcare				
09.10	<b>"Advances in Oncology Drug Discovery"</b> - 09.30 William Pao, Global Head of the Oncology Discovery and Translational Area (DTA), Roche Pharmaceutical Research & Early Development (pRED), F. Hoffmann-La Roche Ltd.				
09.35	<b>"Collaboration Between Big and Small Viewed from Both Sides"</b> Christopher Viehbacher, Managing Partner, Gurnet Point Capital	<b>Presentation Track A</b> Moderated by: Tomas Kahn			
09.55		09.30	DiaMedica Inc. - [TSX-V:DMA] [OTCQB:DMCAF]		
10.00	<b>Global VC Roundtable</b> Co-Chaired by: Bibhash Mukhopadhyay, Principal, New Enterprise Associates Markus Hosang, General Partner, BioMedPartners AG Panellists: Genghis Lloyd-Harris, Partner, Abingworth LLP John Gustofson, Sr. Director, Ventures & Early Stage Collaborations, AbbVie, Inc. Martien van Osch, Managing Partner, Forbion Capital Partners Matthew Foy, Partner, SR One Monique Schiersing, Investment Director, F. Hoffmann-La Roche AG Roche Venture Fund Otello Stampacchia, Managing Director, Omega Funds Tony Rosenberg, Managing Director, MPM Capital LP	09.45	Onconova Therapeutics - [NASDAQ: ONTX]	09.50	[Reserved - InnaVirVax]
		10.00	Double Bond Pharmaceutical AB - [DBPB: SS]	10.00	Mymetics - [OTCMKTS: MYMX]
		10.15	MOLOGEN AG - [MGN: GR]	10.10	Evaxion Biotech
		10.30	4D Pharma Plc. - [LON: DDDD]	10.20	Biologics Resources LLC
		10.45	RXi Pharmaceuticals, Inc. - [NASDAQ: RXII]	10.30	Strekin AG
				10.40	ILTOO Pharma
				10.50	Inflamalps SA
		<b>Presentation Track B</b> Moderated by: Wilder Fulford			

11.00 Coffee							
11.15 - 12.05	<b>Buy-Side Perspectives</b> Chaired by: Bob Pooler, Sr. Healthcare Analyst, valuationLAB AG Panellists: Chris Maggos, Managing Director, Europe, LifeSci Advisors Christian Lach, Senior Portfolio Manager, Bellevue Asset Management AG Ivo Stajjen, Head, Public Equity, HBM Partners AG Kai Brüning, Senior Portfolio Manager, apo Asset Management GmbH Thomas Stockman, Director, Healthcare Investment Banking, Royal Bank of Canada	11.15 - 12.00	<b>Platform Technologies &amp; Novel Therapeutics</b> Chaired by: Jane Atkins, Senior Director, GI Business Development, Takeda Pharmaceuticals International GmbH Jasper Bos, Vice President and Head of Healthcare, Merck Ventures Panellists: Armin Mäder, CEO, Memo Therapeutics AG Omar Haffar, Founder, President and CEO, Eos Biosciences, Inc. Stefan Luzi, Associate, Gilde Healthcare Partners Tibor Papp, Senior Director, Business Development, Haematology / Oncology / Transplantation, Shire Pharmaceuticals	<b>Presentation Track C</b> Moderated by: Oliver Haslam		<b>Presentation Track D</b> Moderated by: TBA	
			11.15	Atlantic Healthcare Plc.	11.15	Pharmasum Therapeutics AS	
			11.30	GeNeuro SA - [GNRO: FP]	11.25	Prexton Therapeutics	
			11.45	[Available]	11.35	Selonterra	
			12.00	CorMedix, Inc. - [NYSEMKT: CRMD]	11.45	Acticor Biotech SAS	
			12.15	Allegra Therapeutics GmbH	11.55	eTheRNA immunotherapies NV	
12.10	<b>Collaborations with Academic Medical Centres</b> Chaired by: Edwin Constable, Vice-Rector Research, University of Basel Luc Otten, Business Development, The Alpine Institute for Drug Discovery Panellists: Carolyn Porter, Deputy Head of Technology Transfer, Oxford University Innovation Ltd. Dani Bach, Investments Director, Imperial Innovations Dior Baumjohann, Technology Manager, Ascenion GmbH Ernst Hafen, President, Bio-Technopark Zurich Maria Bobadilla, Roche Partnering Innovation, F. Hoffmann-La Roche Ltd. TBC, Inserm Transfert	12.00	<b>Autoimmune &amp; Inflammatory Diseases</b> Co-Chaired by: Kia Motesharei, Head, Immunology Licensing, EMD Serono Peter Dudek, Principal, Wellington Partners Panellists: Eric de La Fortelle, Venture Partner, Seventure Partners Jérémie Mariau, CEO, ILTOO Pharma Jesús Martin-Garcia, CEO, GeNeuro SA Lesley Bester, Business Development Director, F. Hoffmann-La Roche Ltd. Simon Blake, Sr. Director Scientific Licensing Immunology, Johnson & Johnson Thomas Hanke, EVP, Head of Immunology & Inflammation, Evotec International GmbH Toby Wilson Waterworth, CEO, Atlantic Healthcare plc	<b>Presentation Track C</b> Moderated by: Oliver Haslam		<b>Presentation Track D</b> Moderated by: TBA	
			12.30	MDxHealth - [MDXH:BB]	12.05	ImmunoMet Therapeutics, Inc.	
			12.45	Novogen Limited - [ASX: NRT]	12.15	Nouscom AG	
					12.25	Provecs Medical GmbH	
					12.35	IO Biotech ApS	
					12.45	ATRIVA Therapeutics GmbH	


Host Sponsor:



Reception Sponsor:



Silver Sponsors:



Bronze Sponsors:



Supporters:



13.00 <u>Networking Lunch</u>							
14.00	<b>Neuroscience I – Alzheimer’s Disease</b> Co-Chaired by: Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research Tim Luker, Senior Director, External Innovation, Corp BD, Eli Lilly and Company Panellists: Carol Routledge, Venture Partner, SV Life Sciences Charles Stacey, President and CEO, Accera, Inc. David Reynolds, CSO, Alzheimer’s Research UK Malcolm Weir, Co-Founder and CEO, Heptares Therapeutics	14.00	<b>Vaccines &amp; Infectious Diseases</b> Co-Chaired by: Chris Britten, Managing Director, Torrey Partners Florian Schödel, Owner, Philimmune, LLC Panellists: Agnete Fredriksen, CSO, Vaccibody AS Frederic Legros, VP Business Development, Valneva SE Joël Crouzet, CEO, InnaVirVax Randy Milby, CEO, CorMedix, Inc. Ronald Kempers, President and CEO, Mymetics SA Nicholas Benedict, Co-founder & CEO, Allecra Therapeutics GmbH	<b>Presentation Track E</b> Moderated by: Chris Maggos		<b>Presentation Track F</b> Moderated by: Luc Otten	
				14.00	[Available]	14.00	Edinburgh Molecular Imaging Ltd.
				14.15	Biophytis	14.10	ProAxis Ltd.
				14.30	Pantarhei Oncology	14.20	Novigenix SA
				14.45	Avexxin AS	14.30	TM3 Therapeutics
				15.00	Eos Biosciences, Inc.	14.40	RDD Pharma
14.35	<b>Neuroscience II – Parkinson’s Disease &amp; Pain</b> Co-Chaired by: Fabrizio Gasparini, Director, Novartis Institutes for BioMedical Research Klaus Mendla, Head of Global Business Development and Licensing CNS, Boehringer Ingelheim Panellists: Arthur Roach, Director of Research, Parkinson’s UK Timothy Morris, CFO, Head of Business Development, AcelRx Pharmaceuticals, Inc. Francois Conquet, CEO, Prexton Therapeutics Jörg Neermann, Partner, LSP Kathryn Gregory, Executive Director, Licensing & Business Development, Purdue Pharma Raghuram Selvaraju, Chairman of the Board of Directors, Relief Therapeutics Holding AG Ronald Notvest, Executive Vice President, Commercial Planning and Development, Tonix Pharmaceuticals Holding Corp.	14.55	<b>Biomarkers &amp; Precision Medicine</b> Co-chaired by: Alain Huriez, Partner, Advent Life Sciences Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH Panellists: Ian Wilson, CEO, Edinburgh Molecular Imaging Ltd. Jan Groen, CEO, MDxHealth Kevin Cox, CEO, Imanova Ltd. Nicolas Demierre, COO, Novigenix	14.50	Ex Scientia Ltd.	15.00	Triskel Biopharmaceuticals AG
				15.15	PeptiMimesis	15.10	Inserm DR Grand-Est
						15.20	CellProthera SAS

15.30	<b>Coffee Break</b>						
15.45	<b><u>Brexit: Implications for European Bio Pharma Innovation and Investment</u></b> Co-Chaired by: John Rountree, Managing Partner, Novasecta Ltd. Mike Ward, Chief Content Officer, Datamonitor Healthcare & Scrip Intelligence, Informa Panellists: Genghis Lloyd-Harris, Partner, Abingworth LLP Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International John Wilkinson, Partner, Cooley LLP Paul Hermant, Head of Corporate Life Sciences, Bird & Bird	15.45	<b><u>Early Stage Investment</u></b> Co-Chaired by: Nooman Haque, Director of Life Sciences, Silicon Valley Bank Steve Dickman, Chief Executive Officer, CBT Advisors Panellists: Alexandra Richardson, Head of Business Development, Clayton Biotechnologies, Inc. Fabian Buller, Director, New Ventures, J&J Innovation Reza Halse, Head, European Innovation Hub, MSD Sofia Ioannidou, Investment Director, Life Sciences, Edmond de Rothschild Investment Partners Ulf Grawunder, CEO & Founder, NBE-Therapeutics Ltd.	<b>Presentation Track G</b> Moderated by: Hans Herklots		<b>Presentation Track H</b> Moderated by: Robin Davison	
				15.45	Sensorion SA - [EPA: ALSEN]	15.45	Medesis Pharma SA
				16.00	Accera, Inc.	15.55	GREENBONE ORTHO SRL
				16.15	Heptares Therapeutics	16.05	Anagenesis Biotechnologies
				16.30	Purdue Pharma L.P.	16.15	Elthera AG
				16.45	Tonix Pharmaceuticals Holding Corp. - [NASDAQ:TNXP]	16.25	3Brain GmbH
				17.00	Relief Therapeutics Holding AG	16.35	[Available]
				17.15	Addex Therapeutics Ltd.	16.45	[Available]
17.15	<b><u>Israel Biomed Panel Discussion</u></b> Chaired by: Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences Panellists: Jason Laufer, CEO, RDD Pharma Michal Silverberg, Senior Director External Innovations, Takeda Ventures Tamar Raz, CEO, Hadasit Ltd. Yigal Yanai, CEO, PlasmaMedic Ltd.	17.15	<b><u>Israel Biomed Panel: Elevator Session</u></b> Chaired by: Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences Presenting companies: Alon Yaar, CEO, Curewize Barak Zigdon, CEO, Z.M.D. Medical Ltd. Issac Tal, CEO, TPCera Jeniffer Yarden, CEO, BioShai Moshik Cohen-Kutner, Co-Founder & CEO, Omnix Medical Ltd. Tahel Altman, CEO, Synvaccine Ltd. Tal Youdim, CTO, N2B Zvica Goltzman, CEO, Saturix Ltd.	16.55	[Available]		
				[Available]			
				[Available]			
18.00	<b>End of The Day 1</b>						
19.00	<b>Networking Reception at the Grand Hotel "Les Trois Rois"</b>						
21.00	<b>End of Reception</b>						

Day 2, 28<sup>th</sup> September 2016

08.00	<b>Registration &amp; Coffee</b>		
08.30	<p><b>Presentation &amp; Discussion on “M&amp;A Deal Tectonics in Pharma &amp; Biotech”</b>                  Featuring:                  Alexander Nuyken, Head of Life Sciences Transaction Advisory EMEA, Ernst &amp; Young GmbH                  Jens Holstein, CFO, Morphosys                  Matthias Bunte, Managing Partner &amp; Advisory Leader Industries Switzerland, Ernst &amp; Young AG</p>		
09.00	<p><b>Partnering: “How to Shape Deal Terms to Execute on Strategic Goals”</b>                  Chaired by:                  Fintan Walton, CEO and Founder, PharmaVentures                  Sarah Holland, Head of Europe, External Science and Partnering, Sanofi SA                  Panellists:                  Florence Dal Degan, R&amp;D Innovation Sourcing Director, Novo Nordisk                  Janette Dean, Executive Director, Business Development Transactions, Bristol-Myers Squibb                  Lubor Gaal, Head of Licensing and External Innovation, Almirall S.A.                  Nathalie ter Wengel, European Head Global Scouting External R&amp;D Innovation, Pfizer                  Paola Casarosa, Corporate Vice President, Business Development &amp; Licensing, Boehringer Ingelheim GmbH                  Paul Hermant, Head of Corporate Life Sciences, Bird &amp; Bird                  Stewart Kay, Director, Business Development, GSK</p>	<b>Presentation Track X</b> Moderated by: Steve Dickman	
		09.00	[Available]
		09.15	[Available]
		09.30	<b>Provectus Biopharmaceuticals, Inc. - [NYSE MKT: PVCT]</b>
		09.45	<b>Targovax ASA</b>
10.00	<b>Coffee Break</b>		

Host Sponsor:



Reception Sponsor:



Silver Sponsors:



Bronze Sponsors:



Supporters:



10.15	<b><u>Oncology I – Partnering &amp; Development Opportunities</u></b> Co-Chaired by: Esteban Pombo-Villar, Independent Consultant Katya Smirnyagina, Partner, Capricorn Venture Partners Panellists: Austin Smith, Medical Director, Theradex (Europe) Ltd. Göran Forsberg, CEO, Cantargia AB Guillaume Vignon, Head of Immuno-Oncology Licensing & Business Development, EMD Serono Juergen Gamer, VP Business Development, Apogenix AG Loic Vincent, Head of Oncology External Innovation, Sanofi Mark Vaeck, CEO, Complix NV Vladimir Cmiljanovic, CEO, PIQUR Therapeutics AG	<b>Presentation Track A</b> Moderated by: Wilder Fulford		<b>Presentation Track B</b> Moderated by: Jørgen Thorball	
		10.15	Galena Biopharma, Inc. – [NASDAQ: GALE]	10.15	Synpromics Ltd.
		10.30	Arsanis, Inc.	10.25	F2G Ltd.
		10.45	AcelRx Pharmaceuticals, Inc. - [NASDAQ: ACRX]	10.35	Clayton Biotechnologies, Inc.
				10.45	Novithera
10.55	Anima Biotech Ltd.				
11.15	<b><u>Oncology II – Advances in IO &amp; Cell Therapy</u></b> Chaired by: Tim Herpin, Vice President, Head of Transactions (UK), Business Development, AstraZeneca Panellists: Anthony DeBoer, Director, Business Development, Synaffix BV Daniel Barton, Director of Business Development, Biosceptre International Ltd. Marina Udier, COO, Nouscom AG Mark Schwartz, President and CEO, Galena Biopharma, Inc. Ramesh Kumar, President and CEO, Onconova Therapeutics Stéphane Degove, CEO, GamaMabs Pharma SA	11.00	Celyad S.A. - [CYAD: BB]	11.05	Lytix Biopharma AS
		11.15	Cellestia Biotech AG	11.15	[Available]
				11.25	[Available]
		11.30	Aurealis Pharma AG	11.35	[Available]
		<b>Presentation Track C</b> Moderated by: Hans Herklots		<b>Presentation Track D</b> Moderated by: Robin Davison	
12.15	<b><u>Advances in Cell &amp; Gene Therapies</u></b> Chaired by: Rao Movva, Novartis Distinguished Scientist (retired) & Currently Independent Biotech Advisor Panellists: David Venables, CEO, Synpromics Ltd. Eric Halioua, President & CEO, PDC*line Pharma Georges Rawadi, VP Business and Development, Celyad S.A. Kilian Guse, CEO, Genequine Biotherapeutics GmbH ZhiZhong Yao, Analyst, Sofinnova Partners	12.00	PIQUR Therapeutics AG	12.00	Apogenix AG
		12.15	GamaMabs Pharma SA	12.15	ImCyse
		12.30	Cantargia AB - [CANTA.ST]	12.30	Biosceptre International Ltd.
		12.45	Synaffix BV	12.45	[Available]
13.00	<b>Networking Lunch</b>				
14.00	<b><u>Interactive Workshop: by Pharma Ventures Ltd.</u></b>				
15.30	<b>Last Chance to Network</b>				
16.30	<b>End of the Forum</b>				